Recent

% | $
Quotes you view appear here for quick access.

Response Genetics, Inc Message Board

  • etradebabysitter etradebabysitter Jan 16, 2014 7:56 PM Flag

    Thomas A. Bologna: Chairman and Chief Executive Officer

    Thomas A. Bologna joined Response Genetics as our Chief Executive Officer in December 2011.

    From April 2006 until joining Response Genetics, Mr. Bologna served as President and Chief Executive Officer of Orchid Cellmark, Inc., a NASDAQ-listed corporation and a leading service provider of DNA identity testing.

    Prior to joining Orchid Cellmark, Mr. Bologna was President, Chief Executive Officer and a member of the board of the venture-backed Quorex Pharmaceuticals, Inc., where he orchestrated a successful sale to Pfizer Inc.

    Prior to leading Quorex, Mr. Bologna was Chairman of the Board, President and Chief Executive Officer of Ostex International, Inc., a NASDAQ-listed biotechnology company that developed and commercialized disease management products with a focus on osteoporosis. Mr. Bologna oversaw the sale of Ostex to Alere Inc. (formally Inverness Medical Innovations).

    Mr. Bologna’s prior experience includes serving as President and Chief Executive Officer of Scriptgen Pharmaceuticals, Inc., a Boston biotechnology start-up company.

    Before leading Scriptgen, Mr. Bologna was Chairman of the Board, President and Chief Executive Officer of Gen-Probe, Incorporated, a global leader in the development, manufacture and marketing of molecular diagnostic products. He led Gen-Probe through its initial public offering on NASDAQ and oversaw its subsequent sale to Chugai Pharmaceutical Co., Ltd.

    Mr. Bologna has also held senior-level positions with Becton Dickinson & Company and Warner-Lambert Company (Pfizer), two leading Fortune 500 healthcare companies.

    Mr. Bologna served as President of the Becton Dickinson Diagnostic Instrument Systems Division and as a Vice President of the Warner-Lambert Company.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thanks for posting all that. It has perked up my interest considerably! I'll check more into it!

      Sentiment: Hold

    • Prior to leading Quorex, Mr. Bologna was Chairman of the Board, President and Chief Executive Officer of Ostex International, Inc., a NASDAQ-listed biotechnology company that developed and commercialized disease management products with a focus on osteoporosis. Mr. Bologna oversaw the sale of Ostex to Alere Inc. (formally Inverness Medical Innovations).

      THOMAS A. BOLOGNA joined Ostex International, Inc. in July 1997 and is the company's Chairman, President and Chief Executive Officer.

      Sep 2, 2001 The Seattle-based medical device company has struggled to increase sales and maintain its stock price since the company went public in 1995. Over the years, Ostex shares dropped drastically from a peak of about $22 in September 1995 to less than a dollar in late 1998. The company's shares were boosted by the recent FDA announcement and are now trading at around $2.66, compared to a yearly low of $1.03 in March.

      WALTHAM, MA and SEATTLE, WA—September 9, 2002—Inverness Medical Innovations, Inc. (Amex: IMA), a leading provider of women's health and nutritional products and developer of advanced medical device technologies, and Ostex International, Inc. (Nasdaq NM: OSTX), a developer and marketer of technologies and products for the management of osteoporosis, announced today that they have signed a definitive merger agreement. The aggregate number of shares of Inverness common stock to be issued in the merger in exchange for Ostex' outstanding shares and to be reserved for the options and warrants to be assumed by Inverness is 2.3 million shares, with each share of Ostex common stock expected to convert into approximately 0.1494 shares of Inverness common stock. Based on Ostex' current capital structure, approximately , 1.88 million shares of IMA common stock are to be issued at closing and approximately 420,000 shares are to be reserved for assumed options and warrants. The transaction is expected to close late in the fourth quarter of 2002 or in the first quarter of 2003.

    • "Orchid Cellmark is one of the world's largest and most experienced AABB accredited DNA Paternity testing."

      "From April 2006 until joining Response Genetics, Mr. Bologna served as President and Chief Executive Officer of Orchid Cellmark, Inc., a NASDAQ-listed corporation and a leading service provider of DNA identity testing. "

      December 16, 2011-
      Laboratory Corporation of America® Holdings (NYSE: LH) today announced the successful completion of the previously announced subsequent offering period for the cash tender offer by its wholly owned subsidiary, OCM Acquisition Corp. (“OCM”), for all outstanding shares of common stock of Orchid Cellmark Inc. (NASDAQ: ORCH) (“Orchid Cellmark”)

      Laboratory Corp. of America Holdings has once again extended its $84 million cash tender offer for Orchid Cellmark Inc. as the medical-testing services provider continues to cooperate with the Federal Trade Commission's request for further information.

      As announced previously, on April 19, 2011, LabCorp, through its wholly owned subsidiary OCM Acquisition Corp., commenced a tender offer for all outstanding shares of Orchid at a price of $2.80 per share net to the seller in cash without interest and subject to applicable withholding taxes.

      4/6/11
      small cap Orchid Cellmark Inc. (ORCH), today’s top Nasdaq stock surging 37.31% on an announcement it is being bought by Laboratory Corp. of America Holdings (LH) for $85.4 million in cash. Lab Corp is itself trading up, something which doesn’t often occur with an acquirer and an indication that the market feels this 40-year old North Carolina clinical testing firm got itself a steal of a deal. Princeton based Orchid is an established presence in legal DNA sequencing, forensics work, at-home kits, and paternity products. Orchid shares, which could be had for as low as $1.35 just before Labor Day, have responded accordingly.

      • 1 Reply to etradebabysitter
      • Prior to joining Orchid Cellmark, Mr. Bologna was President, Chief Executive Officer and a member of the board of the venture-backed Quorex Pharmaceuticals, Inc., where he orchestrated a successful sale to Pfizer Inc.

        Quorex Pharmaceuticals was a drug discovery company applying structure-guided lead optimization technologies across multiple disease categories.

        From 2004 to 2005, Mr. Bologna was Chief Executive Officer, President, and a director of Quorex Pharmaceuticals, Inc., a pre-clinical stage anti-infective company.

        Thomas A. Bologna, who has a reputation on Wall Street for growing and/or selling biotech firms, starts on the job in early April.

        SAN DIEGO, Sept. 14 2004 Quorex Pharmaceuticals, Inc., a
        biotechnology company developing new classes of anti-infective medicines,
        announced the appointment of Thomas A. Bologna as president and chief
        executive officer. Bologna has a 20-year track record of leading
        venture-backed and publicly traded biotechnology companies, turnarounds and
        highly profitable healthcare divisions and subsidiaries of Fortune
        500 companies.

        Bologna was quoted in 2004 as saying that a lot of early-stage drug discovery companies were having a “tough time.” “In the current biotech cycle, people are looking for products that are in the clinic, preferably in Phase 2 testing,” Bologna told the San Diego Union Tribune. Bologna came on as CEO of Quorex in September, 2004, laid nearly everybody off in November, and by December of that year he had sold the firm to Pfizer.

        As of December 31, 2004, Quorex Pharmaceuticals, Inc. was acquired by Pfizer Inc. Quorex Pharmaceuticals, Inc., a drug discovery company, engages in discovering and developing anti-bacterial compounds for community and hospital infections. The company was founded in 1999 and is based in Carlsbad, California.

 
RGDX
0.0250.0000(0.00%)Aug 10 3:59 PMEDT